CREATE Medicines, Inc. (formerly Myeloid Therapeutics) today announced new preclinical data for RetroT, the company's fully RNA-encoded, site-specific gene-integration system, presented at the Cold ...

A hospitalized patient triggers a major setback for Intellia's $1.9B flagship drug, shaking investor faith overnight ...

The goal of gene therapy is to permanently cure hereditary diseases. One of the most promising technologies for this is the ...

To protect themselves against viral infection, bacteria often use CRISPR-Cas systems to identify and destroy an invading virus’s genetic material. But viruses aren’t helpless and can deploy ...

On June 28, 2012, the most significant scientific breakthrough of the first quarter of the 21st century was announced to the ...

CRISPR has a problem: an embarrassment of riches. Ever since the gene editing system rocketed to fame, scientists have been looking for variants with better precision and accuracy. One search method ...

Over the past two decades, the immune system has attracted increasing attention for its role in fighting cancer. As researchers have learned more and more about the cancer-immune system interplay, ...

The colonies of Escherichia coli sitting in this petri dish become pathogenic when they carry Shiga toxin genes. Credit: Shutterstock “We’re essentially converting a pathogenic strain into a ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

Like the find-and-replace feature of a word processor, CRISPR-based engineering allows scientists to quickly and efficiently edit DNA sequences with base pair precision. Lauded as the great ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $62.56, moving -2.51% from the previous trading session. Elsewhere, the Dow saw a downswing of 0.16%, while the tech-heavy Nasdaq ...